Drugs / ALN-SNCA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07216066 | Dec 2025 → Jun 2029 expected | Parkinson disease | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-SNCA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07216066 ↗ |
| Route | Intrathecal | “Intrathecally Administered ALN-SNCA” NCT07216066 ↗ |